Tollys appoints Amina Zinaï, MD, as head of clinical development
Drawing on her expertise, Dr. Zinaï will be supporting Tollys in its early clinical developments.
Tollys welcomes Dr. Jean-Pierre Armand as member of its scientific advisory board
Professor Jean-Yves Blay, current member of the scientific advisory board, takes up chairmanship as company prepares to launch clinical programs.
Tollys appoints Philippe Goupit as chairman of the board
With more than 35 years experience in the pharmaceutical industry and biotech, Philippe Goupit will lead Tollys’ plans for growth.
Tollys extends its executive management team with appointment of Bettina Werle as CSO
Bettina Werle will supervise the laboratory, help set its scientific priorities and lead Tollys’ R&D team.
Tollys receives over €1.5 million deep tech financing from Bpifrance
Support funding for breakthrough innovation will help company’s development in preparation for clinical trials in bladder cancer
Tollys closes pre-Series A financing of €2.3 million
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.
Recent Comments